Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The study objective is to compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The primary study objective is to evaluate the long-term safety of DVS-233 SR during open-label treatment of outpatients with Major Depressive Disorder (MDD).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis
to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings Estudio abierto sobre seguridad y eficacia de ReFacto AF en pacientes no tratados previamente, en condiciones asistenciales habituales
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients less than 6 years of age.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW
To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSE REGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILY FOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEE
To establish efficacy and safety of PLA-695 in subjects with active OA of the knee.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Demonstration of the safety and efficacy of ReFacto AF administered by bolus injection or continuous infusion during the perioperative management of patients with hemophilia A undergoing major surgery
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH DONEPEZIL AS ACTIVE CONTROL
The primary objective is to determine the safety, tolerability, and efficacy of 3 doses of Lecozotan (SRA-333) SR (2 mg, 5 mg and 10 mg) in patients with mild to moderate AD over 12 weeks.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause
To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 5 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Background of Methotrexate
To assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active Rheumatoid Arthritis on a background of methotrexate.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
Next